Najat Khan, the Chief R&D Commercial Officer of $RXRX, sold 36,599 shares of the company on 08-18-2025 for an estimated $202,172. We received data on the trade from a recent SEC filing. This was a sale of approximately 5.2% of their shares of this class of stock. Following this trade, they now own 668,197 shares of this class of $RXRX stock.
$RXRX Insider Trading Activity
$RXRX insiders have traded $RXRX stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $RXRX stock by insiders over the last 6 months:
- CHRISTOPHER GIBSON (Chief Executive Officer) has made 0 purchases and 6 sales selling 796,749 shares for an estimated $4,359,950.
- NAJAT KHAN (Chief R&D Commercial Officer) sold 36,599 shares for an estimated $202,172
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RXRX Hedge Fund Activity
We have seen 167 institutional investors add shares of $RXRX stock to their portfolio, and 179 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. removed 7,725,096 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $40,865,757
- BLACKROCK, INC. added 4,864,474 shares (+20.7%) to their portfolio in Q2 2025, for an estimated $24,614,238
- VANGUARD GROUP INC added 3,783,201 shares (+11.7%) to their portfolio in Q2 2025, for an estimated $19,142,997
- DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) removed 2,315,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $12,246,350
- STATE STREET CORP removed 1,905,719 shares (-14.6%) from their portfolio in Q2 2025, for an estimated $9,642,938
- ARK INVESTMENT MANAGEMENT LLC removed 1,826,871 shares (-5.2%) from their portfolio in Q2 2025, for an estimated $9,243,967
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 1,793,008 shares (-28.0%) from their portfolio in Q2 2025, for an estimated $9,072,620
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$RXRX Analyst Ratings
Wall Street analysts have issued reports on $RXRX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 05/06/2025
To track analyst ratings and price targets for $RXRX, check out Quiver Quantitative's $RXRX forecast page.
$RXRX Price Targets
Multiple analysts have issued price targets for $RXRX recently. We have seen 3 analysts offer price targets for $RXRX in the last 6 months, with a median target of $6.0.
Here are some recent targets:
- Gil Blum from Needham set a target price of $8.0 on 07/08/2025
- Vikram Purohit from Morgan Stanley set a target price of $5.0 on 07/03/2025
- Mani Foroohar from Leerink Partners set a target price of $6.0 on 02/28/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
